Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta
No Definitive Decision Yet On Avenue Deal
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.
